Rheumatoid Arthritis Resource Center

ABP 798, A Rituximab Biosimilar, Safe and Effective in RA Compared to Original, A Comparison of Biosimilar versus Originator Rituximab in RA and Non-Hodgkin’s Lymphoma

Rituximab Increases Risk of Severe COVID-19 in Patients with Rheumatic Disease

Patients with inflammatory rheumatic and musculoskeletal diseases on rituximab therapy may have a greater risk for severe COVID-19, according to a study. “In particular, rituximab...
biosimilar, Etanercept vs. Methotrexate: How Do These Drugs Compare in RA Patients in Remission?

Etanercept vs. Methotrexate: How Do These Drugs Compare in RA Patients in Remission?

Among patients with rheumatoid arthritis (RA) who have achieved remission following combination methotrexate plus etanercept, monotherapy with etanercept was superior to methotrexate, according to...
disease, trump, Hydroxychloroquine, hip arthroplasty, covid-19, postoperative, cancellations, rheumatologists, voltaren, fracture, opioids, TXA, JIA, pain, disease, frailty, violence, rheumatic, acr, cbd, NSAIDs, humira, knee, TJA

Rheum Round-up: Disease Activity Affects COVID-19 Death, CRF and Mortality in RA, and more

Disease Activity, DMARDs May Affect COVID-19 Death Risk in Patients With Rheumatic Disease In addition to known risk factors, including older age and certain comorbidities,...
Reduced Cardiorespiratory Fitness Mediates Excess All-cause Mortality in Rheumatoid Arthritis, CRF, eCRF

Reduced Cardiorespiratory Fitness Mediates Excess All-cause Mortality in Rheumatoid Arthritis

A study found that low cardiorespiratory fitness (CRF) was a mediator of excess all-cause mortality among patients with rheumatoid arthritis (RA) and suggested that...
Risk for Rheumatoid Arthritis Reduced for Patients With T2DM

Risk for Rheumatoid Arthritis Reduced for Patients With T2DM

TUESDAY, Feb. 23, 2021 (HealthDay News) -- Patients with type 2 diabetes mellitus (T2DM) have a reduced risk for rheumatoid arthritis (RA), which may...
Adalimumab, ixekizumab, Humira® No. 1 Drug Linked to $5.1 B Increase in Medical Spending

Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?

An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported outcomes (PROs) in patients with moderate‐to‐severe chronic plaque psoriasis (PsO),...
video

Dr. Nowell Discusses Which PROs Are Most Important To Rheumatology Patients

Benjamin Nowell, Ph.D, Director of Patient-Centered Research, CreakyJoints, and principal investigator of ArthritisPower, discusses the results of a new study, “Which patient-reported outcomes do...

Curated Journal Reading List